Alnylam CEO Maraganore To Step Aside At End Of 2021
Executive Summary
Founding CEO will remain involved with Alnylam’s scientific advisory board, while current president/COO Yvonne Greenstreet will move up to the chief executive’s office.
You may also be interested in...
Omega Launches Aerium With ‘Substantial’ Cash, Two Antibodies Against SARS-CoV-2
Its antibodies will enter the clinic soon, but pandemic- and epidemic-focused Aerium plans to raise series B funds to take the assets all the way to an EUA in the US and pursue antiviral drug development.
RNAi Returns To Spotlight As Novo Nordisk Swoops For Dicerna
The Denmark-headquartered major is impressed with what it has seen in Dicerna in the two years since the companies teamed up and is paying an 80% premium to get hold of the US firm's RNAi technology platforms.
Alnylam’s Vutrisiran NDA Incorporates Earlier Onpattro Trial In hATTR Amyloidosis Patients
Alnylam’s second NDA for an RNA interference treatment for the rare disease rests on a comparison of vutisiran patients in the Phase III HELIOS-A study against an external control arm of placebo patients from Onpattro’s APOLLO study.